Cybin is trading 6.6% down at $10.67, with biotech-sector weakness potentially weighing on shares.
- No clear company-specific catalyst for October 6 has surfaced. The latest related filing headline was dated October 5, and the news page reports no reason for the decline.
- XBI was down 2.50% during the session, while the broader market was higher, making sector pressure a more consistent explanation than a broad-market decline.